Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.
about
Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic ReviewVaccination of adolescents with chronic medical conditions: Special considerations and strategies for enhancing uptakeHistory of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease Prevention.Vaccination in HIV-infected adults.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningocSafety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without InfectionImmunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus.Genetic variants in toll-like receptor 2 (TLR2), TLR4, TLR9, and FCγ receptor II are associated with antibody response to quadrivalent meningococcal conjugate vaccine in HIV-infected youthImmunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth.Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015.Immunization of HIV-infected adult patients - French recommendations.Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-DT): a multicenter, open-label, non-randomized, phase III clinical trial.Baseline Circulating Activated TFH and Tissue-Like Exhausted B Cells Negatively Correlate With Meningococcal C Conjugate Vaccine Induced Antibodies in HIV-Infected Individuals
P2860
Q26700078-F425866B-F1D1-498F-8654-EC2B29AA3F23Q26799457-F134B09F-E948-4942-AB59-11A6E0465155Q30249427-2C79D7CA-D36C-471D-92FC-AE3FD8149C4FQ33980764-56305253-171C-4F7A-B585-D28A2899F9AFQ34212799-7C3EAFB8-904E-4831-88FF-7217F21F6B47Q34390072-523E12A2-42E2-4873-A643-835B1DF6F7CDQ34739055-B47A5D04-63E4-42B4-9E8E-8684C19453B2Q35655927-5BA31A38-A036-4952-8ED3-1F6909C54E7EQ35680467-1DFBD595-844A-4425-B94F-C8E3FA34238AQ35999709-F6BE82A3-0874-42E3-8959-EA6A88028B2BQ36210265-8BC2A8D3-57A0-4FCB-B9AF-279B40C0E8ABQ36911285-67D6B967-D2C8-4FFE-95E2-90649CE6D90FQ40275424-FDF9B67E-7FB5-4604-BD4B-250FA3BB1770Q40408137-BCD739A4-E46C-4BE9-BC90-C940D7E29500Q40560650-1033963F-C1DF-4C9F-81FC-FB4515E73EF0Q40615516-EF560741-3954-498E-81D0-A8518DA1F02BQ41488993-79296983-71B7-44CC-A4A0-A4293AA55CF8Q42669782-0D153523-5CD7-48D6-8A55-E17B49B5462EQ58694946-9E495910-FCFE-4753-B4F8-8C1D5FB75B4E
P2860
Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase I/II, open-label trial o ...... cy virus-infected adolescents.
@ast
Phase I/II, open-label trial o ...... cy virus-infected adolescents.
@en
type
label
Phase I/II, open-label trial o ...... cy virus-infected adolescents.
@ast
Phase I/II, open-label trial o ...... cy virus-infected adolescents.
@en
prefLabel
Phase I/II, open-label trial o ...... cy virus-infected adolescents.
@ast
Phase I/II, open-label trial o ...... cy virus-infected adolescents.
@en
P2093
P2860
P921
P1476
Phase I/II, open-label trial o ...... cy virus-infected adolescents.
@en
P2093
Barbara E Heckman
Emily F Demske
George K Siberry
IMPAACT P1065 Protocol Team
Jennifer S Read
Jorge Lujan-Zilbermann
Meredith G Warshaw
Paige L Williams
Patrick Jean-Philippe
Sharon Nachman
P2860
P304
P356
10.1097/INF.0B013E3181C38F3B
P577
2010-05-01T00:00:00Z